Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part ...

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Vor Biopharma (VOR – Research Report). The associated price ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

In a recent publication in Nature Communications, researchers from the Tumor Profiler consortium combined single-cell multi-omics and functional profiling for 21 AML patients to reveal resistance ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

A pioneering Finnish study has shown that drug sensitivity testing can help pinpoint which leukemia patients are likely to ...

Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target. Shares fell 6.7% to 16 cents. The Rockville, Maryland-based ...

On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated ...